Could a 'Cellular Age' test predict lung problems in preemies?
NCT ID NCT03540680
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether a marker of cellular aging called p16Ink4a is linked to bronchopulmonary dysplasia (BPD), a serious lung disease in premature babies. Researchers measured p16 levels in blood from 80 newborns and children, comparing those with and without BPD. The goal was to better understand the disease's causes, not to test a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help researchers understand why some premature babies develop long-term lung problems and point toward future treatments.
- What could go wrong
- This is a small, completed observational study that only measures biological markers, not a treatment. It may not lead to any direct medical advances.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Mother's Omega-3 supplement shield preterm Babies' lungs?
- A new MRI test could spot a hidden Heart-Lung danger in babies
- Early therapy may rewire motor development in premature infants
- Can scans and scope tests unlock better care for tiny lungs?
- Which inhaler works best for preterm children with lung disease? a study seeks answers
- Human milk mouth care may shield preemies from lung infections